Intravenous Thrombolysis With Low-dose Recombinant Tissue Plasminogen Activator in Central Retinal Artery Occlusion

American Journal of Ophthalmology

Volumn 146, Issue 5, 2008, Pages

  Hattenbach, Lars Olof ^a,b   Kuhli Hattenbach, Claudia ^a   Scharrer, Inge ^a   Baatz, Holger ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Augenklinik des Klinikums Ludwigshafen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; HEPARIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CENTRAL RETINA ARTERY OCCLUSION; CLINICAL ARTICLE; DRUG CONTRAINDICATION; FEMALE; HEPARINIZATION; HUMAN; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 54449094941     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.06.016     Document Type: Article

References (37)

1. Hölschermann H., Krombach C., Jung A., Jacobi F., Tillmanns H., and Weinand F. Treatment of acute central retinal artery occlusion with the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban. Thromb Haemost 94 (2005) 684-686
2. Rumelt S., Dorenboim Y., and Rehany U. Aggressive systematic treatment for central retinal artery occlusion. Am J Ophthalmol 128 (1999) 733-738
3. Mueller A.J., Neubauer A.S., Schaller U., Kampik A., and European Assessment Group for Lysis in the Eye. Evaluation of minimally invasive therapies and rationale for a prospective randomized trial to evaluate selective intra-arterial lysis for clinically complete central retinal artery occlusion. Arch Ophthalmol 121 (2003) 1377-1381
4. Reynard M., and Hanscom T.A. Neodymium:yttrium-aluminum-garnet laser arteriotomy with embolectomy for central retinal artery occlusion. Am J Ophthalmol 137 (2004) 196-198
5. Garcia-Arumi J., Martinez-Castillo V., Boixadera A., Fonollosa A., and Corcostegui B. Surgical embolus removal in retinal artery occlusion. Br J Ophthalmol 90 (2006) 1252-1255
6. Vine A.K., Maguire P.T., Martonyi C., and Kincaid M.C. Recombinant tissue plasminogen activator to lyse experimentally induced retinal arterial thrombi. Am J Ophthalmol 105 (1988) 266-270
7. Schmidt D., Schumacher M., and Wakhloo A.K. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 113 (1992) 429-434
8. Schumacher M., Schmidt D., and Wakhloo A.K. Intraarterial fibrinolytic therapy in central retinal artery occlusion. Neuroradiology 35 (1993) 600-605
9. Richard G., Lerche R.C., Knospe V., and Zeumer H. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator. Ophthalmology 106 (1999) 768-773
10. Beatty S., and Au Eong K.G. Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data. Br J Ophthalmol 84 (2000) 914-916
11. Schmidt D.P., Schulte-Mönting J., and Schumacher M. Prognosis of central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment. Am J Neuroradiol 23 (2002) 1301-1307
12. Butz B., Strotzer M., Manke C., Roider J., Link J., and Lenhart M. Selective intraarterial fibrinolysis of acute central retinal artery occlusion. Acta Radiol 44 (2003) 680-684
13. Arnold M., Koerner U., Remonda L., et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatr 76 (2005) 196-199
14. Feltgen N., Neubauer A., Jurklies B., et al., EAGLE-Study Group. Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study Report No. 1. Graefes Arch Clin Exp Ophthalmol 244 (2006) 950-956
15. Kattah J.C., Wang D.Z., and Reddy C. Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion. Arch Ophthalmol 120 (2002) 1234-1236
16. von Mach M.A., Güz A., Wiechelt J., Pfeiffer N., and Weilemann L.S. Systemic fibrinolytic therapy using urokinase in central retinal artery occlusion. A case study [in German]. Dtsch Med Wochenschr 130 (2005) 1002-1006
17. Bertram B., Wolf S., Fisches H., et al. Thrombolytic treatment of retinal arterial occlusions with plasminogen activator [in German]. Klin Monatsbl Augenheilkd 198 (1991) 295-300
18. Sloan M., and Gore J.M. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis. Am J Cardiol 69 (1992) A21-A38
19. Anderson J.L., Karagounis L., Allan A., Bradford M.J., Menlove R.L., and Pryor T.A. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 68 (1991) 166-170
20. Hayreh S.S., Zimmermann M.B., Kimura A., and Sanon A. Central retinal artery occlusion. Retinal survival time. Exp Eye Res 78 (2004) 723-736
21. Augsburger J.J., and Magargal L.E. Visual prognosis following treatment of acute central retinal artery obstruction. Br J Ophthalmol 64 (1980) 913-917
22. Greven C.M., Slusher M.M., and Weaver R.G. Retinal arterial occlusions in young adults. Am J Ophthalmol 120 (1995) 776-783
23. Ramakrishna G., Malouf J.F., Younge B.R., Connolly H.M., and Miller F.A. Calcific retinal embolism as an indicator of severe unrecognised cardiovascular disease. Heart 91 (2005) 1154-1157
24. Biousse V., Calvetti O., Bruce B.B., and Newman N.J. Thrombolysis for central retinal artery occlusion. J Neuroophthalmol 27 (2007) 215-230
25. Lindsberg P.J., and Mattle H.P. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 37 (2006) 922-928
26. Hacke W., Kaste M., Fieschi C., et al., ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study Group (ECASS). JAMA 274 (1995) 1017-1025
27. Suri M.F., Nasar A., Hussein H.M., Divani A.A., and Qureshi A.I. Intra-arterial thrombolysis for central retinal artery occlusion in the United States: Nationwide In-patient Survey 2001-2003. J Neuroimaging 17 (2007) 339-343
28. Menon V., Harrington R.A., Hochman J.S., et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) S549-S575
29. Brott T.G., Haley Jr. E.C., and Levy D.E. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23 (1992) 632-640
30. Haley Jr. E.C., Levy D.E., and Brott T.G. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 23 (1992) 641-645
31. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
32. The GUSTO angiographic investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329 (1993) 1615-1622
33. Hattenbach L.O., Steinkamp G.W.K., Scharrer I., and Ohrloff C. Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 212 (1998) 394-398
34. Biousse V., and Trobe J.D. Transient monocular visual loss. Am J Ophthalmol 140 (2005) 717-721
35. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333 (1995) 1581-1587
36. Kwiatkowski T.G., Libman R.B., Frankel M., et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 340 (1999) 1781-1787
37. The TOAST investigators. Low molecular weight heparinoid, Org 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA 279 (1998) 1265-1272